Bergera koenigii (Murraya koenigii) Leaf Extract Face Serum for the Reduction of Hyperpigmentation and Dark Spots: A Phytopharmaceutical Review and Formulation Approach

Abstract

Hyperpigmentary disorders — melasma, post-inflammatory hyperpigmentation (PIH), solar lentigines, and idiopathic dark spots — remain among the most common reasons patients with photo-exposed and darker skin types seek dermatological care, particularly across the Indian subcontinent. Conventional depigmenting actives such as hydroquinone, kojic acid, and synthetic tyrosinase inhibitors carry recognized concerns of cutaneous irritation, ochronosis, and limited long-term tolerability, sustaining interest in standardized herbal alternatives. Bergera koenigii L. (synonym Murraya koenigii (L.) Spreng., Rutaceae), the Indian curry leaf tree, is a rich source of pyranocarbazole alkaloids (mahanimbine, girinimbine, mahanine, koenimbine) and flavonoids (rutin, quercetin, kaempferol glycosides) with documented antioxidant, anti-inflammatory, antimicrobial, and wound-healing activity. This review consolidates the botanical, phytochemical, and pharmacological evidence relevant to cutaneous pigmentation and proposes a Quality-by-Design (QbD) based approach for developing a B. koenigii leaf extract face serum. A critical, and often overlooked, observation emerging from the literature is that the depigmenting potential of B. koenigii is extract-dependent: an aqueous leaf extract has been reported to inhibit mushroom tyrosinase, whereas a steam-distilled essential-oil fraction from the same species has been reported to activate tyrosinase several-fold. This contradiction carries direct formulation consequences and is addressed explicitly in the proposed extraction and quality-control strategy. The review further outlines candidate critical quality attributes, a representative formulation composition, evaluation parameters (physicochemical, in vitro antioxidant and tyrosinase-inhibition assays, dermal safety, and stability), and identifies the principal research gaps — extract standardization, seasonal/geographic alkaloid variability, and the absence of human clinical efficacy data — that must be resolved before B. koenigii can be confidently positioned as a depigmenting cosmeceutical active.

Keywords